FATE logo

FATE Fate Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$1.05
-0.09 (-8.18%)

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute my…

Market Cap: $122.01Mwww.fatetherapeutics.com

Price

No data yet.

Social Signal Score

57
5d
—
30d
57
1 mentions
—
60d
63
2 mentions
—
90d
52
3 mentions
—
news: 3

Analyst Ratings

31 analysts
Buyconsensus
Strong Buy 0Buy 16Hold 13Sell 2Strong Sell 0
Avg price target$5.63+437.8%
Low $3.5Median $5.5High $8
Current Consensus

Revenue

$0.00-100.00%
$0.00$19.66M$39.32M$58.98M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.15
$-1.17–$-1.10
7 analysts
FY2026
$-1.02
$-1.12–$-0.83
7 analysts
FY2027
$-1.04
$-1.41–$-0.61
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Bahram Valamehr
Sector
Healthcare
Industry
Biotechnology
Employees
161
Beta
2.67
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-9.97
www.fatetherapeutics.com